Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) traded down 9.3% on Tuesday . The company traded as low as $5.72 and last traded at $5.77. 679,137 shares traded hands during trading, a decline of 80% from the average session volume of 3,473,137 shares. The stock had previously closed at $6.36. Analyst Ratings Changes […]
Should You Buy or Sell Fate Therapeutics Stock? Get The Latest FATE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Fate Therapeutics (NASDAQ:FATE – Get Rating) will release its earnings data after the market closes on Wednesday, May 3rd. Analysts expect Fate Therapeutics to post earnings of ($0.55) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. Fate Therapeutics (NASDAQ:FATE – Get […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating)’s share price dropped 9.3% on Tuesday . The stock traded as low as $5.72 and last traded at $5.77. Approximately 679,137 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 3,473,137 shares. The stock had previously closed at $6.36. Analyst Upgrades […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) Director Redmile Group, Llc bought 20,000 shares of the stock in a transaction that occurred on Thursday, April 20th. The shares were bought at an average price of $5.99 per share, for a total transaction of $119,800.00. Following the completion of the transaction, the director now directly owns […]